Shenzhen Boluote Biological Products Co., Ltd. won the 2020 Shenzhen Science and Technology-Patent Award.

The Shenzhen Patent Award was established by the Shenzhen Municipal People's Government to encourage and commend Shenzhen enterprises and inventors for their outstanding contributions in technological innovation and accelerating the construction of an innovative country. It is reported that the Shenzhen Patent Award is selected once a year, and 25 award-winning patents are selected each year. This time, Shenzhen Borlaut was able to win this award in Shenzhen, where top companies gather, which is the Shenzhen Municipal Government's full affirmation of the company's innovative research capabilities and intellectual property protection capabilities.

Data and flow regulation data show that the infection rate of Helicobacter pylori (HP) in our country exceeds 50%. According to simple eradication treatment (quadruple therapy: 2 kinds of antibiotics + proton pump + bismuth), people in my country who use antibiotics for a short period of time There will be more than 700 million people, which will have a huge burden on the national medical insurance system and public health resources, and will also have a huge negative impact on the national health.

For several years, Burlaut has been deeply rooted in the field of Helicobacter pylori precision diagnosis, and completed the research project: "The biological characteristics and clinical application of CagA and VacA, the key pathogenic factors of Helicobacter pylori", which reveals that CagA and VacA are Helicobacter pylori The key pathogenic factor of bacteria is of great significance to the precise diagnosis and treatment of Helicobacter pylori, and won the second prize of the National Science and Technology Progress Award.

The in-vitro diagnostic reagent product "Helicobacter pylori antibody typing test kit (Western blotting)" corresponding to this patent award of Burlaut Biology can not only confirm the existence of Helicobacter pylori infection, but also further the virulence and pathogenicity of bacteria. Disease evaluation; thereby providing accurate clinical diagnosis and treatment services, avoiding excessive medical treatment, rationally allocating medical resources, and improving the deterioration of Helicobacter pylori antibiotic resistance, which has major health, economic and social benefits.

Patented technology is not only a portrayal of national strength, but also the fundamental survival of a science and technology company, behind which is the technical strength. In the future, Shenzhen Burot will continue to work in the field of biotechnology, and through unremitting technological innovation and intellectual property system construction, to ensure that technological innovation and market creation can bring long-term value to the company and society!